 Mark Clements
Concepts (474)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 91 | 2024 | 108 | 27.380 |
Why?
| | Blood Glucose | 41 | 2024 | 53 | 6.150 |
Why?
| | Insulin | 32 | 2024 | 46 | 5.620 |
Why?
| | Hypoglycemia | 21 | 2023 | 26 | 5.480 |
Why?
| | Blood Glucose Self-Monitoring | 30 | 2024 | 32 | 4.830 |
Why?
| | Hypoglycemic Agents | 29 | 2024 | 32 | 4.820 |
Why?
| | Humans | 132 | 2024 | 6599 | 4.350 |
Why?
| | Male | 88 | 2024 | 3197 | 3.690 |
Why?
| | Parents | 21 | 2023 | 149 | 3.290 |
Why?
| | Adolescent | 64 | 2024 | 2087 | 3.200 |
Why?
| | Insulin Infusion Systems | 15 | 2023 | 16 | 3.180 |
Why?
| | Child | 66 | 2024 | 3146 | 3.170 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2023 | 44 | 3.140 |
Why?
| | Female | 76 | 2024 | 3436 | 3.080 |
Why?
| | Prostatic Neoplasms | 8 | 2024 | 17 | 2.760 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 21 | 2.340 |
Why?
| | Hyperglycemia | 8 | 2022 | 10 | 2.280 |
Why?
| | Adult | 39 | 2023 | 1233 | 2.250 |
Why?
| | Depression | 9 | 2022 | 68 | 2.230 |
Why?
| | Child, Preschool | 32 | 2022 | 1459 | 2.100 |
Why?
| | Mass Screening | 5 | 2022 | 41 | 1.630 |
Why?
| | Registries | 13 | 2022 | 85 | 1.590 |
Why?
| | Middle Aged | 26 | 2021 | 648 | 1.560 |
Why?
| | Self Care | 5 | 2018 | 24 | 1.470 |
Why?
| | Caregivers | 5 | 2022 | 38 | 1.450 |
Why?
| | Patient Compliance | 6 | 2017 | 70 | 1.240 |
Why?
| | Diabetic Ketoacidosis | 4 | 2022 | 4 | 1.160 |
Why?
| | Biomedical Technology | 3 | 2023 | 5 | 1.140 |
Why?
| | Aged | 17 | 2024 | 375 | 1.120 |
Why?
| | Medication Adherence | 4 | 2018 | 59 | 1.070 |
Why?
| | Telemedicine | 3 | 2021 | 64 | 1.070 |
Why?
| | Meals | 7 | 2024 | 13 | 1.030 |
Why?
| | Magnetic Resonance Imaging | 4 | 2024 | 114 | 1.030 |
Why?
| | Sweden | 14 | 2022 | 27 | 1.000 |
Why?
| | Mobile Applications | 4 | 2020 | 17 | 0.990 |
Why?
| | Surveys and Questionnaires | 9 | 2023 | 290 | 0.970 |
Why?
| | Thromboembolism | 1 | 2023 | 3 | 0.940 |
Why?
| | Risk Assessment | 5 | 2021 | 130 | 0.930 |
Why?
| | Neuralgia | 1 | 2023 | 1 | 0.930 |
Why?
| | Hyperalgesia | 1 | 2023 | 2 | 0.930 |
Why?
| | Glucose | 8 | 2024 | 22 | 0.920 |
Why?
| | Time Factors | 3 | 2021 | 241 | 0.900 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 10 | 0.890 |
Why?
| | Young Adult | 15 | 2021 | 652 | 0.870 |
Why?
| | Social Support | 1 | 2022 | 38 | 0.860 |
Why?
| | Risk Factors | 10 | 2023 | 460 | 0.850 |
Why?
| | Retrospective Studies | 9 | 2023 | 1251 | 0.810 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 36 | 0.810 |
Why?
| | Capillaries | 1 | 2021 | 1 | 0.810 |
Why?
| | Blood Specimen Collection | 1 | 2021 | 4 | 0.800 |
Why?
| | Family Conflict | 3 | 2021 | 3 | 0.790 |
Why?
| | Cost of Illness | 2 | 2020 | 19 | 0.790 |
Why?
| | Insulin-Secreting Cells | 4 | 2023 | 4 | 0.780 |
Why?
| | Self Efficacy | 2 | 2017 | 28 | 0.740 |
Why?
| | Aging | 2 | 2019 | 32 | 0.740 |
Why?
| | Quality Improvement | 2 | 2019 | 60 | 0.710 |
Why?
| | Health Plan Implementation | 1 | 2019 | 10 | 0.710 |
Why?
| | Fear | 6 | 2023 | 17 | 0.700 |
Why?
| | Child Development | 1 | 2019 | 42 | 0.700 |
Why?
| | Diet, Diabetic | 2 | 2015 | 4 | 0.680 |
Why?
| | Prospective Studies | 13 | 2022 | 508 | 0.670 |
Why?
| | Cross-Sectional Studies | 13 | 2022 | 317 | 0.640 |
Why?
| | Adolescent Behavior | 3 | 2016 | 47 | 0.640 |
Why?
| | Feeding Behavior | 2 | 2018 | 51 | 0.620 |
Why?
| | Parenting | 4 | 2018 | 24 | 0.620 |
Why?
| | Quality of Life | 3 | 2022 | 131 | 0.610 |
Why?
| | Follow-Up Studies | 13 | 2022 | 315 | 0.600 |
Why?
| | United States | 9 | 2021 | 646 | 0.580 |
Why?
| | Reproducibility of Results | 7 | 2023 | 197 | 0.580 |
Why?
| | Biomarkers | 6 | 2021 | 120 | 0.550 |
Why?
| | Child Behavior | 3 | 2016 | 30 | 0.550 |
Why?
| | Albuminuria | 1 | 2015 | 12 | 0.550 |
Why?
| | Algorithms | 1 | 2016 | 103 | 0.540 |
Why?
| | Food | 1 | 2015 | 18 | 0.530 |
Why?
| | Models, Biological | 3 | 2019 | 46 | 0.490 |
Why?
| | Health Education | 1 | 2014 | 39 | 0.470 |
Why?
| | Early Detection of Cancer | 2 | 2024 | 8 | 0.450 |
Why?
| | Infant | 11 | 2020 | 1396 | 0.450 |
Why?
| | Insulins | 2 | 2022 | 2 | 0.440 |
Why?
| | Family | 2 | 2022 | 26 | 0.430 |
Why?
| | Treatment Outcome | 7 | 2022 | 624 | 0.430 |
Why?
| | Minority Groups | 4 | 2019 | 18 | 0.420 |
Why?
| | Crohn Disease | 2 | 2022 | 21 | 0.410 |
Why?
| | Sleep | 4 | 2021 | 36 | 0.410 |
Why?
| | Age of Onset | 4 | 2020 | 27 | 0.400 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2021 | 40 | 0.390 |
Why?
| | Cohort Studies | 6 | 2022 | 264 | 0.380 |
Why?
| | Mothers | 2 | 2023 | 37 | 0.380 |
Why?
| | Models, Organizational | 1 | 2020 | 8 | 0.380 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 10 | 0.370 |
Why?
| | Prostate-Specific Antigen | 4 | 2024 | 4 | 0.370 |
Why?
| | Research Design | 1 | 2020 | 64 | 0.360 |
Why?
| | Biomedical Research | 1 | 2020 | 20 | 0.360 |
Why?
| | Dietary Carbohydrates | 2 | 2020 | 4 | 0.360 |
Why?
| | C-Peptide | 4 | 2023 | 5 | 0.360 |
Why?
| | Behavior Therapy | 2 | 2022 | 41 | 0.350 |
Why?
| | Exercise | 4 | 2024 | 125 | 0.350 |
Why?
| | Pilot Projects | 3 | 2022 | 124 | 0.350 |
Why?
| | Prevalence | 5 | 2022 | 145 | 0.340 |
Why?
| | Case-Control Studies | 4 | 2023 | 202 | 0.330 |
Why?
| | Longitudinal Studies | 4 | 2018 | 123 | 0.320 |
Why?
| | Australia | 5 | 2022 | 9 | 0.320 |
Why?
| | Incidence | 4 | 2021 | 125 | 0.320 |
Why?
| | Sudden Infant Death | 2 | 1998 | 2 | 0.320 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2018 | 80 | 0.320 |
Why?
| | Austria | 4 | 2020 | 4 | 0.310 |
Why?
| | Germany | 4 | 2020 | 6 | 0.310 |
Why?
| | Hope | 2 | 2018 | 3 | 0.310 |
Why?
| | Socioeconomic Factors | 5 | 2020 | 63 | 0.300 |
Why?
| | Parent-Child Relations | 4 | 2022 | 33 | 0.300 |
Why?
| | Ambulatory Care Facilities | 2 | 2019 | 38 | 0.300 |
Why?
| | Ustekinumab | 2 | 2022 | 2 | 0.270 |
Why?
| | Patient Education as Topic | 4 | 2018 | 64 | 0.260 |
Why?
| | Developed Countries | 3 | 2020 | 3 | 0.260 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 99 | 0.260 |
Why?
| | Accelerometry | 2 | 2022 | 44 | 0.260 |
Why?
| | Motivation | 2 | 2022 | 64 | 0.250 |
Why?
| | Aged, 80 and over | 3 | 2020 | 150 | 0.250 |
Why?
| | Infant, Newborn | 6 | 2020 | 790 | 0.250 |
Why?
| | Sick Leave | 2 | 2022 | 2 | 0.240 |
Why?
| | Proportional Hazards Models | 4 | 2017 | 34 | 0.240 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2023 | 2 | 0.240 |
Why?
| | Sex Factors | 4 | 2020 | 71 | 0.240 |
Why?
| | Pediatrics | 2 | 2019 | 170 | 0.240 |
Why?
| | Myelodysplastic Syndromes | 1 | 2023 | 11 | 0.240 |
Why?
| | Stress, Psychological | 3 | 2020 | 33 | 0.240 |
Why?
| | Genetic Therapy | 1 | 2023 | 5 | 0.230 |
Why?
| | Interleukin-10 | 1 | 2023 | 5 | 0.230 |
Why?
| | Health Personnel | 2 | 2022 | 28 | 0.230 |
Why?
| | DNA | 1 | 2023 | 39 | 0.230 |
Why?
| | Prediabetic State | 1 | 2022 | 3 | 0.220 |
Why?
| | Prostate | 2 | 2021 | 2 | 0.220 |
Why?
| | Carrier Proteins | 3 | 2017 | 32 | 0.220 |
Why?
| | Cholera | 1 | 2022 | 1 | 0.220 |
Why?
| | Cholera Vaccines | 1 | 2022 | 1 | 0.220 |
Why?
| | Islets of Langerhans | 2 | 2013 | 3 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 62 | 0.220 |
Why?
| | Self-Injurious Behavior | 1 | 2022 | 2 | 0.220 |
Why?
| | Plant Viruses | 1 | 2022 | 1 | 0.210 |
Why?
| | Orchidaceae | 1 | 2022 | 1 | 0.210 |
Why?
| | RNA Viruses | 1 | 2022 | 3 | 0.210 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 61 | 0.210 |
Why?
| | Problem Behavior | 1 | 2022 | 7 | 0.210 |
Why?
| | Comorbidity | 1 | 2022 | 61 | 0.210 |
Why?
| | Income | 2 | 2020 | 17 | 0.210 |
Why?
| | Colitis, Ulcerative | 1 | 2021 | 9 | 0.210 |
Why?
| | Quality-Adjusted Life Years | 1 | 2021 | 2 | 0.210 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2021 | 2 | 0.200 |
Why?
| | ABO Blood-Group System | 1 | 2021 | 11 | 0.200 |
Why?
| | Disease Susceptibility | 1 | 2021 | 10 | 0.200 |
Why?
| | Veins | 1 | 2021 | 4 | 0.200 |
Why?
| | Inflammation | 2 | 2019 | 48 | 0.200 |
Why?
| | Postprandial Period | 3 | 2020 | 14 | 0.200 |
Why?
| | Conservation of Natural Resources | 1 | 2021 | 1 | 0.200 |
Why?
| | Rainforest | 1 | 2021 | 1 | 0.200 |
Why?
| | Child Health | 1 | 2021 | 7 | 0.200 |
Why?
| | Specimen Handling | 1 | 2021 | 18 | 0.200 |
Why?
| | Diabetes Complications | 1 | 2020 | 1 | 0.200 |
Why?
| | Midwestern United States | 5 | 2021 | 39 | 0.200 |
Why?
| | Pediatric Obesity | 1 | 2023 | 127 | 0.200 |
Why?
| | Hospitalization | 1 | 2022 | 192 | 0.190 |
Why?
| | Disease Management | 2 | 2019 | 36 | 0.190 |
Why?
| | Efficiency | 1 | 2020 | 1 | 0.190 |
Why?
| | Dihydroxycholecalciferols | 1 | 2020 | 1 | 0.190 |
Why?
| | Patient Care | 1 | 2020 | 6 | 0.190 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 1 | 0.190 |
Why?
| | Life Change Events | 1 | 2020 | 4 | 0.190 |
Why?
| | Vitamin D | 1 | 2020 | 21 | 0.190 |
Why?
| | Watchful Waiting | 1 | 2020 | 7 | 0.190 |
Why?
| | Health Care Costs | 1 | 2020 | 29 | 0.190 |
Why?
| | Risk | 3 | 2015 | 40 | 0.190 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 145 | 0.180 |
Why?
| | Animals | 7 | 2017 | 563 | 0.180 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 41 | 0.180 |
Why?
| | Professional Practice | 1 | 2019 | 4 | 0.180 |
Why?
| | Luxembourg | 1 | 2019 | 1 | 0.180 |
Why?
| | Datasets as Topic | 1 | 2019 | 7 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2019 | 22 | 0.180 |
Why?
| | Healthcare Disparities | 1 | 2019 | 20 | 0.180 |
Why?
| | Reference Values | 3 | 2015 | 40 | 0.180 |
Why?
| | Insulin, Regular, Human | 3 | 2024 | 3 | 0.180 |
Why?
| | Androgen-Binding Protein | 1 | 1999 | 1 | 0.180 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 24 | 0.180 |
Why?
| | Testosterone | 1 | 1999 | 11 | 0.180 |
Why?
| | Saliva | 1 | 1999 | 10 | 0.180 |
Why?
| | Atherosclerosis | 1 | 2019 | 2 | 0.170 |
Why?
| | Program Evaluation | 1 | 2019 | 52 | 0.170 |
Why?
| | Feeding and Eating Disorders | 1 | 2019 | 8 | 0.170 |
Why?
| | Carbohydrates | 1 | 2018 | 2 | 0.170 |
Why?
| | Authoritarianism | 1 | 2018 | 1 | 0.170 |
Why?
| | Oxidative Stress | 2 | 2015 | 13 | 0.170 |
Why?
| | Nutrition Surveys | 1 | 2018 | 7 | 0.170 |
Why?
| | Dyslipidemias | 1 | 2018 | 14 | 0.170 |
Why?
| | Nutritional Status | 1 | 2018 | 14 | 0.160 |
Why?
| | Prognosis | 4 | 2020 | 209 | 0.160 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2018 | 2 | 0.160 |
Why?
| | Eating | 1 | 2018 | 28 | 0.160 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 22 | 0.160 |
Why?
| | Papillomavirus Infections | 1 | 2018 | 7 | 0.160 |
Why?
| | Delivery of Health Care | 2 | 2019 | 29 | 0.160 |
Why?
| | Diabetic Angiopathies | 1 | 2017 | 1 | 0.160 |
Why?
| | Endothelium, Vascular | 1 | 2017 | 5 | 0.160 |
Why?
| | Aortic Diseases | 1 | 2017 | 4 | 0.160 |
Why?
| | Pandemics | 3 | 2023 | 78 | 0.150 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 24 | 0.150 |
Why?
| | ROC Curve | 3 | 2022 | 18 | 0.150 |
Why?
| | Stroke | 1 | 2017 | 24 | 0.150 |
Why?
| | Blood Pressure | 1 | 2017 | 56 | 0.150 |
Why?
| | Health Behavior | 1 | 2017 | 72 | 0.140 |
Why?
| | Hypertension | 1 | 2017 | 59 | 0.140 |
Why?
| | Sleep Deprivation | 1 | 2016 | 1 | 0.140 |
Why?
| | Neoplasm Grading | 3 | 2021 | 18 | 0.140 |
Why?
| | Optimism | 1 | 2015 | 2 | 0.140 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2015 | 1 | 0.140 |
Why?
| | Nutrition Policy | 1 | 2015 | 5 | 0.140 |
Why?
| | Child Nutrition Sciences | 1 | 2015 | 3 | 0.140 |
Why?
| | Heart Failure | 1 | 2015 | 14 | 0.140 |
Why?
| | Metformin | 1 | 2015 | 5 | 0.140 |
Why?
| | Forkhead Transcription Factors | 1 | 2015 | 5 | 0.140 |
Why?
| | Food Supply | 1 | 2015 | 10 | 0.130 |
Why?
| | Osteocalcin | 1 | 2015 | 1 | 0.130 |
Why?
| | Kansas | 1 | 2015 | 49 | 0.130 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 8 | 0.130 |
Why?
| | Insurance Coverage | 1 | 2015 | 19 | 0.130 |
Why?
| | Endothelial Cells | 1 | 2015 | 23 | 0.130 |
Why?
| | Rats | 4 | 2017 | 97 | 0.130 |
Why?
| | Sunlight | 1 | 2014 | 1 | 0.120 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2014 | 1 | 0.120 |
Why?
| | Ultraviolet Rays | 1 | 2014 | 5 | 0.120 |
Why?
| | Calcifediol | 1 | 2014 | 3 | 0.120 |
Why?
| | Lymphocytes | 1 | 2014 | 15 | 0.120 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 181 | 0.120 |
Why?
| | Body Mass Index | 1 | 2015 | 155 | 0.120 |
Why?
| | Health Planning | 1 | 2013 | 2 | 0.120 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 1 | 0.120 |
Why?
| | Cyclin D1 | 1 | 2013 | 2 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2013 | 7 | 0.120 |
Why?
| | Forecasting | 1 | 2013 | 20 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2013 | 17 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2013 | 8 | 0.120 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 8 | 0.120 |
Why?
| | DNA Methylation | 1 | 2014 | 108 | 0.110 |
Why?
| | Marital Therapy | 1 | 1993 | 1 | 0.110 |
Why?
| | Marriage | 1 | 1993 | 2 | 0.110 |
Why?
| | Double-Blind Method | 2 | 2023 | 48 | 0.110 |
Why?
| | Signal Transduction | 1 | 2013 | 107 | 0.110 |
Why?
| | Communication | 1 | 1993 | 54 | 0.110 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 98 | 0.110 |
Why?
| | RNA, Viral | 2 | 2022 | 16 | 0.110 |
Why?
| | Cell Cycle Proteins | 3 | 2017 | 15 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 3 | 2017 | 46 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2013 | 55 | 0.110 |
Why?
| | Remission Induction | 2 | 2022 | 25 | 0.100 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2011 | 1 | 0.100 |
Why?
| | Bone Marrow | 1 | 2011 | 6 | 0.100 |
Why?
| | Graft Survival | 1 | 2011 | 31 | 0.100 |
Why?
| | Neoplasms | 1 | 2013 | 119 | 0.100 |
Why?
| | Internationality | 2 | 2021 | 5 | 0.100 |
Why?
| | Cholesterol, LDL | 2 | 2023 | 7 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2020 | 26 | 0.090 |
Why?
| | Anxiety | 2 | 2020 | 45 | 0.090 |
Why?
| | England | 2 | 2020 | 2 | 0.090 |
Why?
| | Norway | 2 | 2020 | 2 | 0.090 |
Why?
| | Wales | 2 | 2020 | 2 | 0.090 |
Why?
| | Mice | 3 | 2015 | 290 | 0.080 |
Why?
| | New Zealand | 2 | 1998 | 4 | 0.080 |
Why?
| | Hepatectomy | 1 | 2007 | 4 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 22 | 0.080 |
Why?
| | Liver Diseases | 1 | 2007 | 17 | 0.080 |
Why?
| | Electronic Health Records | 2 | 2018 | 61 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2017 | 6 | 0.070 |
Why?
| | Liver | 1 | 2007 | 119 | 0.070 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 51 | 0.070 |
Why?
| | Transcription Factors | 2 | 2015 | 46 | 0.070 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 178 | 0.060 |
Why?
| | Cardiovascular Diseases | 2 | 2015 | 49 | 0.060 |
Why?
| | Sports | 1 | 2004 | 4 | 0.060 |
Why?
| | Athletic Injuries | 1 | 2004 | 3 | 0.060 |
Why?
| | Workload | 1 | 2004 | 9 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 10 | 0.060 |
Why?
| | Uncertainty | 1 | 2023 | 10 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2013 | 107 | 0.060 |
Why?
| | Snacks | 1 | 2023 | 6 | 0.060 |
Why?
| | Isoantibodies | 1 | 2023 | 8 | 0.060 |
Why?
| | Erythrocytes | 1 | 2023 | 11 | 0.060 |
Why?
| | Age Factors | 2 | 2015 | 203 | 0.060 |
Why?
| | Hemoglobins | 1 | 2023 | 26 | 0.060 |
Why?
| | Verapamil | 1 | 2023 | 3 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 64 | 0.060 |
Why?
| | Overweight | 1 | 2023 | 48 | 0.060 |
Why?
| | Space Perception | 1 | 1982 | 2 | 0.060 |
Why?
| | Reference Standards | 1 | 2022 | 15 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 16 | 0.060 |
Why?
| | Autoantibodies | 1 | 2022 | 9 | 0.060 |
Why?
| | Risk-Taking | 1 | 2022 | 11 | 0.050 |
Why?
| | Travel | 1 | 2022 | 6 | 0.050 |
Why?
| | Interleukin-23 | 1 | 2022 | 2 | 0.050 |
Why?
| | Administration, Oral | 1 | 2022 | 59 | 0.050 |
Why?
| | Plant Diseases | 1 | 2022 | 1 | 0.050 |
Why?
| | Suicidal Ideation | 1 | 2022 | 7 | 0.050 |
Why?
| | Genome, Viral | 1 | 2022 | 4 | 0.050 |
Why?
| | Viral Proteins | 1 | 2022 | 8 | 0.050 |
Why?
| | Phylogeny | 1 | 2022 | 21 | 0.050 |
Why?
| | Disease Progression | 1 | 2022 | 104 | 0.050 |
Why?
| | Executive Function | 1 | 2022 | 11 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 1999 | 65 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2015 | 73 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2021 | 1 | 0.050 |
Why?
| | Random Allocation | 1 | 2021 | 7 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 8 | 0.050 |
Why?
| | Chronic Disease | 1 | 2021 | 103 | 0.050 |
Why?
| | Blood Donors | 1 | 2021 | 1 | 0.050 |
Why?
| | Kidney Calculi | 1 | 2021 | 1 | 0.050 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2021 | 1 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 8 | 0.050 |
Why?
| | Bedding and Linens | 2 | 1998 | 2 | 0.050 |
Why?
| | Blood Transfusion | 1 | 2021 | 13 | 0.050 |
Why?
| | Forests | 1 | 2021 | 1 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2021 | 25 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 94 | 0.050 |
Why?
| | Seasons | 1 | 2021 | 27 | 0.050 |
Why?
| | Photography | 1 | 2020 | 4 | 0.050 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 4 | 0.050 |
Why?
| | Avoidance Learning | 1 | 2020 | 6 | 0.050 |
Why?
| | Benchmarking | 1 | 2020 | 11 | 0.050 |
Why?
| | Survival Analysis | 1 | 2020 | 46 | 0.050 |
Why?
| | Pensions | 1 | 2020 | 1 | 0.050 |
Why?
| | Prostatectomy | 1 | 2020 | 1 | 0.050 |
Why?
| | Pregnancy | 1 | 2021 | 203 | 0.050 |
Why?
| | Radiotherapy | 1 | 2020 | 5 | 0.050 |
Why?
| | Emigrants and Immigrants | 1 | 2019 | 2 | 0.050 |
Why?
| | Infusion Pumps, Implantable | 1 | 2019 | 2 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2020 | 46 | 0.050 |
Why?
| | Longevity | 1 | 2019 | 3 | 0.050 |
Why?
| | Health Educators | 1 | 2019 | 1 | 0.050 |
Why?
| | Linear Models | 1 | 2019 | 55 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2019 | 66 | 0.040 |
Why?
| | Autoradiography | 1 | 1999 | 1 | 0.040 |
Why?
| | Electrophoresis | 1 | 1999 | 1 | 0.040 |
Why?
| | Dihydrotestosterone | 1 | 1999 | 1 | 0.040 |
Why?
| | Dimerization | 1 | 1999 | 3 | 0.040 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 3 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 6 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 1999 | 27 | 0.040 |
Why?
| | Homozygote | 1 | 1999 | 18 | 0.040 |
Why?
| | E-Selectin | 1 | 2019 | 1 | 0.040 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2019 | 6 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2019 | 16 | 0.040 |
Why?
| | Medical Overuse | 1 | 2018 | 1 | 0.040 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2018 | 2 | 0.040 |
Why?
| | Computers, Handheld | 1 | 2018 | 11 | 0.040 |
Why?
| | User-Computer Interface | 1 | 2018 | 10 | 0.040 |
Why?
| | Gene Expression | 2 | 2015 | 60 | 0.040 |
Why?
| | Denmark | 1 | 2018 | 1 | 0.040 |
Why?
| | Data Collection | 1 | 2018 | 32 | 0.040 |
Why?
| | Scandinavian and Nordic Countries | 1 | 2018 | 1 | 0.040 |
Why?
| | Health Policy | 1 | 2018 | 13 | 0.040 |
Why?
| | Databases as Topic | 1 | 2017 | 2 | 0.040 |
Why?
| | Psychometrics | 1 | 2018 | 33 | 0.040 |
Why?
| | Glycemic Index | 1 | 2017 | 2 | 0.040 |
Why?
| | Genetic Variation | 1 | 1999 | 161 | 0.040 |
Why?
| | Directive Counseling | 1 | 2016 | 6 | 0.040 |
Why?
| | Breast Feeding | 1 | 1996 | 23 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2016 | 7 | 0.040 |
Why?
| | Schools, Veterinary | 1 | 1976 | 1 | 0.040 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 1995 | 1 | 0.030 |
Why?
| | Gonads | 1 | 1995 | 1 | 0.030 |
Why?
| | Adrenal Glands | 1 | 1995 | 5 | 0.030 |
Why?
| | Diabetic Nephropathies | 1 | 2015 | 3 | 0.030 |
Why?
| | Cause of Death | 1 | 2015 | 11 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 1995 | 35 | 0.030 |
Why?
| | Peer Influence | 1 | 2015 | 2 | 0.030 |
Why?
| | Diet Records | 1 | 2015 | 6 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2015 | 1 | 0.030 |
Why?
| | Thioredoxins | 1 | 2015 | 1 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2015 | 6 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 9 | 0.030 |
Why?
| | Cytosol | 1 | 2015 | 13 | 0.030 |
Why?
| | Aorta | 1 | 2015 | 8 | 0.030 |
Why?
| | Food Preferences | 1 | 2015 | 12 | 0.030 |
Why?
| | Caspase 7 | 1 | 2015 | 1 | 0.030 |
Why?
| | Caspase 3 | 1 | 2015 | 3 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 4 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 16 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 2015 | 24 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 19 | 0.030 |
Why?
| | Mitochondria | 1 | 2015 | 9 | 0.030 |
Why?
| | Critical Illness | 1 | 2015 | 21 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2015 | 45 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 31 | 0.030 |
Why?
| | Apoptosis | 1 | 2015 | 43 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 87 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 92 | 0.030 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2014 | 1 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 1994 | 1 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 1994 | 18 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 7 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2013 | 10 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 3 | 0.030 |
Why?
| | Survivors | 1 | 2013 | 17 | 0.030 |
Why?
| | Phosphorylation | 1 | 2013 | 21 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 9 | 0.030 |
Why?
| | Survival Rate | 1 | 2013 | 84 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2013 | 7 | 0.030 |
Why?
| | Time | 1 | 2013 | 6 | 0.030 |
Why?
| | Glucagon | 1 | 2013 | 3 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2013 | 12 | 0.030 |
Why?
| | Cell Line | 1 | 2013 | 80 | 0.030 |
Why?
| | Pancreas | 1 | 2013 | 9 | 0.030 |
Why?
| | Recurrence | 1 | 2013 | 115 | 0.030 |
Why?
| | Protein Binding | 1 | 2013 | 30 | 0.030 |
Why?
| | Problem Solving | 1 | 1993 | 2 | 0.030 |
Why?
| | Proteomics | 1 | 2013 | 19 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2013 | 34 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 40 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 1994 | 75 | 0.030 |
Why?
| | Folic Acid | 1 | 2011 | 16 | 0.030 |
Why?
| | Methotrexate | 1 | 2011 | 27 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2011 | 2 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2011 | 4 | 0.030 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 2 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2011 | 4 | 0.030 |
Why?
| | Arthritis, Juvenile | 1 | 2011 | 30 | 0.030 |
Why?
| | Osteoblasts | 1 | 2011 | 21 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 109 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 395 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2011 | 170 | 0.020 |
Why?
| | Integrin alpha6 | 1 | 2007 | 1 | 0.020 |
Why?
| | Oncostatin M | 1 | 2007 | 1 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2007 | 2 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2007 | 2 | 0.020 |
Why?
| | Hepatocytes | 1 | 2007 | 6 | 0.020 |
Why?
| | Cell Separation | 1 | 2007 | 5 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2007 | 5 | 0.020 |
Why?
| | Antigens, CD | 1 | 2007 | 8 | 0.020 |
Why?
| | Glycoproteins | 1 | 2007 | 9 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2007 | 26 | 0.020 |
Why?
| | Peptides | 1 | 2007 | 9 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2007 | 41 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2007 | 43 | 0.020 |
Why?
| | Phenotype | 1 | 2007 | 233 | 0.020 |
Why?
| | New South Wales | 1 | 2004 | 1 | 0.020 |
Why?
| | Causality | 1 | 2004 | 10 | 0.020 |
Why?
| | Thinking | 1 | 1982 | 2 | 0.010 |
Why?
| | Psychology, Adolescent | 1 | 1982 | 6 | 0.010 |
Why?
| | Rehabilitation Centers | 1 | 1977 | 2 | 0.010 |
Why?
| | Alcoholism | 1 | 1977 | 5 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 1977 | 32 | 0.010 |
Why?
| | Agriculture | 1 | 1976 | 1 | 0.010 |
Why?
| | Education, Veterinary | 1 | 1976 | 1 | 0.010 |
Why?
| | Financing, Government | 1 | 1976 | 1 | 0.010 |
Why?
| | School Admission Criteria | 1 | 1976 | 1 | 0.010 |
Why?
| | History, 19th Century | 1 | 1976 | 1 | 0.010 |
Why?
| | Education | 1 | 1976 | 3 | 0.010 |
Why?
| | History, 20th Century | 1 | 1976 | 5 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1995 | 1 | 0.010 |
Why?
| | Steroidogenic Factor 1 | 1 | 1995 | 1 | 0.010 |
Why?
| | Zinc Fingers | 1 | 1995 | 2 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1995 | 5 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1995 | 9 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1995 | 4 | 0.010 |
Why?
| | Repressor Proteins | 1 | 1995 | 12 | 0.010 |
Why?
| | DNA Primers | 1 | 1995 | 27 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1995 | 18 | 0.010 |
Why?
| | Mice, Knockout | 1 | 1995 | 54 | 0.010 |
Why?
| | Placenta | 1 | 1995 | 19 | 0.010 |
Why?
| | Base Sequence | 1 | 1995 | 76 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1995 | 34 | 0.010 |
Why?
| | Clothing | 1 | 1994 | 1 | 0.010 |
Why?
| | Skin Temperature | 1 | 1994 | 1 | 0.010 |
Why?
| | Temperature | 1 | 1994 | 10 | 0.010 |
Why?
| | Acute Disease | 1 | 1994 | 71 | 0.010 |
Why?
| | Maryland | 1 | 1977 | 3 | 0.000 |
Why?
| | Evaluation Studies as Topic | 1 | 1977 | 7 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|